The Diplomat Pharmacy (DPLO) Receiving Somewhat Positive Press Coverage, Study Shows

The Diplomat Pharmacy (DPLO) Receiving Somewhat Positive Press Coverage, Study Shows

Here are some of the headlines that may have impacted AlphaOne’s rankings:

Media coverage about Diplomat Pharmacy (NYSE:DPLO) has been trending somewhat positive this week, according to AlphaOne Sentiment. The research group, a service of Accern, rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Diplomat Pharmacy earned a news sentiment score of 0.12 on AlphaOne’s scale. AlphaOne also gave news headlines about the company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the near term.

DPLO has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Monday, February 6th. Mizuho reissued a “neutral” rating and set a $17.00 target price on shares of Diplomat Pharmacy in a research note on Wednesday, March 1st. Cowen and Company boosted their target price on shares of Diplomat Pharmacy from $12.00 to $17.00 and gave the company a “market perform” rating in a research note on Tuesday, May 9th. Barclays PLC set a $20.00 target price on shares of Diplomat Pharmacy and gave the company a “buy” rating in a research note on Tuesday, May 9th. Finally, Leerink Swann reissued a “market perform” rating and set a $18.00 target price (up from $16.00) on shares of Diplomat Pharmacy in a research note on Wednesday, May 17th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. Diplomat Pharmacy presently has a consensus rating of “Hold” and an average price target of $21.07. Diplomat Pharmacy (NYSE:DPLO) traded down 0.94% during trading on Friday, hitting $17.83. 326,991 shares of the stock were exchanged. The stock has a 50 day moving average price of $16.67 and a 200-day moving average price of $14.85. The firm has a market capitalization of $1.20 billion, a PE ratio of 71.04 and a beta of 0.69. Diplomat Pharmacy has a 12-month low of $12.25 and a 12-month high of $38.94.

Diplomat Pharmacy Company Profile Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “DPLO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Diplomat Pharmacy Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Diplomat Pharmacy Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment